Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575735 | 0.82 | CYP3A4 (0.56) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL5485187 | 0.82 | CYP3A4 (0.56) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL4460807 | 0.81 | CYP3A4 (0.50) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL2173898 | 0.80 | AOX1 (0.47) | TSHRAOX1 | |
| SCHEMBL28793503 | 0.80 | TSHR (0.42) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL28226198 | 0.80 | CYP3A4 (0.54) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL575803 | 0.80 | CYP3A4 (0.64) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3623029 | 0.79 | CYP3A4 (0.48) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL27845160 | 0.79 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR1LPAR2FAAH | |
| SCHEMBL2375833 | 0.77 | CYP3A4 (0.53) | CYP3A4TSHRLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139714-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols-acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-09-22 | — | — | US | disclosed |
| EP-2367834-B1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACROLEINS AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-12-11 | — | — | EP | disclosed |
| US-8604108-B2 | Method for producing mono-hydroxyfunctionalized dialkylphosphinic acids and esters and salts thereof by means of acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-10 | — | — | US | disclosed |
| EP-2346885-B1 | METHOD FOR PRODUCING MONO-CARBOXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | CLARIANT INT LTD (CH) | 2013-08-28 | — | — | EP | disclosed |
| US-20110237720-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Vinyl Compounds and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-29 | — | — | US | disclosed |
| EP-2367834-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACROLEINS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110224339-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Acroleins and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-15 | — | — | US | disclosed |
| US-20110213062-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkyphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-08-18 | — | — | US | disclosed |
| EP-2352737-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF VINYL COMPOUNDS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2346885-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-07-27 | — | — | EP | disclosed |
| EP-2346886-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF AND USE THEREOF | Clariant Finance (BVI) Limited (VG) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010051883-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS/ACROLEINS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051889-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051885-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACROLEINS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051887-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF VINYL COMPOUNDS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213062-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkyphosphinic Acids and Esters and Salts Thereof and Use Thereof | HAO2, HACL2, ACSL3 | CYP3A4 2061/4885TSHR 1746/4885LPAR3 348/4885 |
| US-20110224339-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Acroleins and Use Thereof | HAO2, AOC3, AOC2 | CYP3A4 1643/4885TSHR 965/4885LPAR3 328/4885 |
| US-20110237720-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Vinyl Compounds and Use Thereof | ACSL3, ACSL6, ACSL1 | CYP3A4 2260/4885TSHR 2065/4885LPAR3 657/4885 |
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | AOC3, SCO2, AOC2 | CYP3A4 3011/4885TSHR 715/4885LPAR3 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.